<DOC>
	<DOCNO>NCT00423891</DOCNO>
	<brief_summary>The purpose clinical study determine appropriate dos entecavir use child adolescent . Safety , tolerability efficacy also study</brief_summary>
	<brief_title>A Study Entecavir Pediatric Patients With Chronic Hepatitis B Virus ( HBV ) -Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>218 year age Group A : Lamivudine naive ( &lt; 1 week Lamivudine ) within 24 week screen ; Group B : Lamivudine experience ( &gt; 12 week Lamivudine ) ; Group C : nucleoside/nucleotide experience ( &gt; 12 week nucleoside/tide therapy ) add countryspecific protocol amendment ( site Group C ) . HBV Deoxyribonucleic acid ( DNA ) ≥ 100000 copies/mL ; ≥ 10000 copy nucleoside/nucleotide experience ( Group C ) Detectable Hepatitis B surface antigen ( HBsAg ) 24 week prior screen Hepatitis B e antigen ( HBeAg ) positive Compensated liver renal function Elevated alanine aminotransferase ( ALT ) screen 24 week prior screen ( Groups A B ) Coinfection Human immunodeficiency virus ( HIV ) , Hepatitis C virus ( HCV ) , Hepatitis D Virus ( HDV ) Children breastfed mother received Lamivudine , child whose mother receive Lamivudine pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>